Stock Blog Hub » Biotechnology

(BIIB) Biogen Analyst Neutral on Shares

vitalstocks — Sat, 21 Jan 2012 20:38:57 +0000

We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex, posted sales of $2,518.4 million, up 8.4%, in 2010. We expect Avonex [...]

(BIIB) Biogen Analyst Neutral on Shares

(ILMN) Two Major Biotech Trends In 2012

InvestmentU — Thu, 19 Jan 2012 23:34:54 +0000

by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood for the J.P. Morgan Healthcare Conference drank their fill of Patron, ate [...]

(ILMN) Two Major Biotech Trends In 2012

(CELG) Celgene Corporation – Bull of the Day

vitalstocks — Wed, 18 Jan 2012 20:45:55 +0000

We are maintaining our Outperform recommendation on Celgene Corp. (CELG) following impressive preliminary results disclosed for the fourth quarter (adjusted EPS up 46%) and full year 2011 (adjusted EPS up 36%). Preliminary adjusted revenues in the final quarter of 2011 came in at $1.28 billion, 22% above the year-ago figure. For 2011, sales came in [...]

(CELG) Celgene Corporation – Bull of the Day

(VPHM) ViroPharma Drug Earns Priority Review

vitalstocks — Mon, 16 Jan 2012 23:37:42 +0000

ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s approval for the treatment of prevention, pre-procedure prevention, and treatment of attacks of hereditary angioedema (HAE) in patients who are six years or older. The company [...]

(VPHM) ViroPharma Drug Earns Priority Review

(QGEN) Qiagen Expands with New Deals

vitalstocks — Fri, 13 Jan 2012 21:09:44 +0000

In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration [...]

(QGEN) Qiagen Expands with New Deals

(ITMN) InterMune Fourth Quarter Esbriet Sales Snapshot

vitalstocks — Fri, 13 Jan 2012 20:59:35 +0000

InterMune, Inc. (ITMN) recently reported preliminary fourth quarter revenue for its potential blockbuster drug Esbriet. Esbriet is approved in the European Union (EU) for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). The drug has been launched first in Germany in September 2011. InterMune also announced updated data from the drug’s RECAP study. Preliminary Esbriet [...]

(ITMN) InterMune Fourth Quarter Esbriet Sales Snapshot

(ALNY) Alnylam States Preclinical Data

vitalstocks — Tue, 03 Jan 2012 19:15:26 +0000

Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of [...]

(ALNY) Alnylam States Preclinical Data

(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union

vitalstocks — Thu, 15 Dec 2011 10:00:22 +0000

Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines Agency (EMA) cleared Dificlir for the treatment of clostridium difficile-associated diarrhea (CDAD) also known as clostridium difficile infection (CDI). CDAD is the most common nosocomial or hospital-acquired diarrhea [...]

(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union

(OPTR) Optimer Pharmaceuticals Moved Down to Neutral

vitalstocks — Wed, 14 Dec 2011 20:48:24 +0000

We recently downgraded our rating on Optimer Pharmaceuticals Inc. (OPTR) to Neutral from Outperform as we await more visibility on how the commercial launch of its sole marketed antibiotic Dificid (fidaxomicin) takes shape. Optimer launched Dificid in July 2011 in the US for the treatment of clostridium difficile-associated diarrhea (CDAD). CDAD is the most common [...]

(OPTR) Optimer Pharmaceuticals Moved Down to Neutral

(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress

vitalstocks — Wed, 14 Dec 2011 20:17:36 +0000

Recently, BioMarin Pharmaceutical Inc. (BMRN) commenced a mid-stage study of its pipeline candidate GALNS (N-acetylgalactosamine 6-sulfatase) in children suffering from mucopolysaccharidosis IVA (MPS IVA), a rare genetic enzyme deficiency disorder. The company intends to evaluate the safety and tolerability of the drug dosed at 2.0 mg/kg/week over a period of one year. The study will [...]

(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress

(MITI) Micromet Analyst Maintains Neutral on Shares

vitalstocks — Fri, 09 Dec 2011 17:40:57 +0000

We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 13 cents [...]

(MITI) Micromet Analyst Maintains Neutral on Shares

(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish

vitalstocks — Thu, 08 Dec 2011 17:05:51 +0000

We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this [...]

(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish

(MITI) Micromet Begins New Trial

vitalstocks — Tue, 06 Dec 2011 19:36:44 +0000

Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US Food & Drug Administration (FDA) to support accelerated approval of blinatumomab. The trial is a [...]

(MITI) Micromet Begins New Trial

(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment

vitalstocks — Fri, 02 Dec 2011 16:19:15 +0000

Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study is being conducted in RSV-infected lung transplant patients at 33 lung transplant centers in six countries. Data [...]

(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment

(GILD) Gilead’s Eviplera Drug is Cleared by European Medicines Agency

vitalstocks — Wed, 30 Nov 2011 19:44:00 +0000

Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment of HIV in previously untreated adults. The STR combines Gilead’s marketed HIV drug Truvada (a fixed-dose, once-daily tablet containing Gilead’s Viread and Emtriva) and Johnson and [...]

(GILD) Gilead’s Eviplera Drug is Cleared by European Medicines Agency

(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data

vitalstocks — Mon, 28 Nov 2011 16:32:53 +0000

Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR). Data from the trials showed that ALN-TTR01 [...]

(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data

(ITMN) InterMune Reports Quarterly Loss Smaller Than Estimates

vitalstocks — Thu, 10 Nov 2011 17:45:35 +0000

InterMune, Inc. (ITMN) posted third-quarter adjusted loss per share of 63 cents, wider than the year-ago loss per share of 44 cents due to higher operating expenses. The loss was, however, narrower than the Zacks Consensus Estimate of a loss per share of 73 cents resulting from lower-than-expected R&D expenses. InterMune reported revenues of $5.2 [...]

(ITMN) InterMune Reports Quarterly Loss Smaller Than Estimates

(MDVN) Medivation Incorporated – Bull of the Day

vitalstocks — Mon, 07 Nov 2011 15:14:15 +0000

Medivation, Inc. (MDVN) shares received a major boost recently with the company and its partner, Astellas, reporting impressive data on MDV3100 from a pre-specified interim analysis of a phase III study, AFFIRM. The Independent Data Monitoring Committee (IDMC) recommended that MDV3100′s risk-to-benefit ratio was favorable enough to stop the study. Medivation and Astellas intend to [...]

(MDVN) Medivation Incorporated – Bull of the Day

(DNDN) Dendreon Loss Narrows

vitalstocks — Sun, 06 Nov 2011 19:55:48 +0000

Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus Estimate of 70 cents due to a slightly better-than-expected performance of its prostate cancer vaccine Provenge in the quarter. Loss was, however, much wider than the year-ago [...]

(DNDN) Dendreon Loss Narrows

(VPHM) ViroPharma Going Strong

vitalstocks — Fri, 04 Nov 2011 18:37:45 +0000

ViroPharma Inc. (VPHM) posted third quarter 2011 earnings (including special items) of 35 cents per share, surpassing the Zacks Consensus Estimate of 33 cents, but lower than the year-ago figure of 45 cents. Excluding special items, but including stock based compensation expense, earnings came in at 52 cents per share for the third quarter, reflecting [...]

(VPHM) ViroPharma Going Strong

(THRX) Theravance Third Quarter Loss Deteriorates

vitalstocks — Wed, 02 Nov 2011 21:01:46 +0000

Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was attributable to a lukewarm top-line performance as well as increased research and development (R&D) expenses. Revenue at [...]

(THRX) Theravance Third Quarter Loss Deteriorates

(HGSI) Human Genome Sciences – Bear of the Day

vitalstocks — Tue, 01 Nov 2011 20:44:42 +0000

We are downgrading Human Genome Sciences Inc. (HGSI) to Underperform from Neutral following the disappointing third quarter 2011 results reported by the company. The company suffered a wider-than-expected loss due to lower revenues. The most alarming factor was the below-par showing of Human Genome’s recently launched lupus drug, Benlysta. Following the lackluster showing, we have [...]

(HGSI) Human Genome Sciences – Bear of the Day

(CELG) Celgene Corporation – Bull of the Day

vitalstocks — Wed, 26 Oct 2011 13:43:09 +0000

We are upgrading Celgene Corporation (CELG) to Outperform from Neutral following strong second quarter results delivered by the company and the decision of CHMP that the benefits associated with Revlimid outweigh the risks in multiple myeloma patients. Celgene performed impressively in the second quarter of 2011 and beat the Zacks Consensus Estimate both in terms [...]

(CELG) Celgene Corporation – Bull of the Day

(AMLN) Amylin Pharmaceuticals Posts Lower Loss

vitalstocks — Tue, 25 Oct 2011 17:38:34 +0000

Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses led to the lower year-over-year loss. Third quarter revenues, which included a $15 [...]

(AMLN) Amylin Pharmaceuticals Posts Lower Loss

(CTIC) Cell Therapeutics Incorporated – Bull of the Day

vitalstocks — Thu, 13 Oct 2011 16:31:47 +0000

In late September, Cell Therapeutics (CTIC) announced that a second independent radiologic review of data from the pivotal trial PIX301 of lead drug pixantrone for aggressive NHL confirmed the statistical significance of response and progression endpoints. With this positive development, we believe pixantrone is getting closer to approval. We are encouraged by the FDA’s decision [...]

(CTIC) Cell Therapeutics Incorporated – Bull of the Day

(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress

vitalstocks — Thu, 06 Oct 2011 23:38:53 +0000

Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates a situation where the cholesterol levels in the blood are higher than normal. The randomized, single-blind, placebo-controlled, single-ascending dose study intends to [...]

(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress

(ACOR) Company News for October 6, 2011 – Corporate Summary

vitalstocks — Thu, 06 Oct 2011 17:43:05 +0000

• Monsanto Co. (NYSE:MON) reported its fiscal fourth-quarter loss of $0.22 cents a share, better than the Zacks Consensus Estimate of a loss of $0.27. Revenues rose 15.1% year-over-year to $2.25 billion from $1.95 billion • Reacting to news that Microsoft (NASDAQ:MSFT) is considering a bid for Yahoo (NASDAQ:YHOO), shares of the company gained 3.30% [...]

(ACOR) Company News for October 6, 2011 – Corporate Summary

(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut

vitalstocks — Tue, 27 Sep 2011 20:45:43 +0000

Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline at Enzon was reduced drastically in the last few months. During the second quarter, Enzon announced that it will no longer develop three messenger ribonucleic acid [...]

(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut

(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals

vitalstocks — Sat, 24 Sep 2011 18:58:12 +0000

Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals Inc. (WPI) regarding the generic version of Sanofi-Aventis’ (SNY) Lovenox. The lawsuit was filed in United States District Court for the District of Massachusetts. The lawsuit claims that Amphastar Pharma’s generic Lovenox, which was approved by the US [...]

(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals

(MRX) Medicis Pharmaceutical Sells LipoSonix Business

vitalstocks — Tue, 20 Sep 2011 20:26:12 +0000

Medicis Pharmaceutical Corp. (MRX) recently announced to have entered into a ‘Stock Purchase Agreement’ with Solta Medical, Inc. (SLTM), under which the latter will acquire all the outstanding shares of Medicis Technologies Corporation (formerly LipoSonix, Inc.), a subsidiary of Medicis Pharma. The deal is expected to close in the fourth quarter of 2011. According to [...]

(MRX) Medicis Pharmaceutical Sells LipoSonix Business

(VPHM) ViroPharma and Halozyme Therapeutics Begin Trial

vitalstocks — Mon, 19 Sep 2011 20:40:15 +0000

ViroPharma Inc. (VPHM) and its partner Halozyme Therapeutics (HALO) recently announced the initiation of a mid-stage trial on its drug Cinryze. The phase II study is designed to evaluate the safety, and pharmacokinetics and pharmacodynamics of the subcutaneous formulation of Cinryze in combination with Halozyme’s Enhanze technology, in patients suffering from hereditary angioedema (HAE). Cinryze [...]

(VPHM) ViroPharma and Halozyme Therapeutics Begin Trial

(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell

vitalstocks — Thu, 15 Sep 2011 17:49:51 +0000

We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active metabolite of the cancer drug, irinotecan, for the treatment of metastatic colorectal [...]

(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell

(DNDN) Dendreon Analyst Maintains Neutral on Shares

vitalstocks — Wed, 14 Sep 2011 16:42:37 +0000

We have maintained a Neutral rating on Dendreon Corporation (DNDN) with a target price of $13 per share after appraisal of the second quarter 2011 results. Dendreon Corporation reported weaker-than-expected second quarter 2011 sales of $49.6 million of its potential blockbuster prostate cancer vaccine Provenge, though up from prior quarters. Revenues also disappointed the Zacks [...]

(DNDN) Dendreon Analyst Maintains Neutral on Shares

(ACHN) Company News for September 9, 2011 – Corporate Summary

vitalstocks — Fri, 09 Sep 2011 17:31:05 +0000

• Smithfield Foods (NYSE:SFD) posted Q1 EPS of $0.69, surpassing the Zacks Consensus Estimate of $0.68 per share. Revenues for the quarter rose 6.6% year-over-year to $3.09 billion • PerkinElmer, Inc. (NYSE:PKI) said it will acquire Caliper Life Sciences Inc. (NASDAQ:CALP) in a deal worth about $600 million. Following this development, shares of the genomic-detection [...]

(ACHN) Company News for September 9, 2011 – Corporate Summary

(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares

vitalstocks — Tue, 30 Aug 2011 21:15:16 +0000

We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug [...]

(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares

(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation

vitalstocks — Mon, 22 Aug 2011 14:47:13 +0000

We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta earlier in the year for treating patients suffering from systemic lupus erythematosus (SLE) is a huge positive for [...]

(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation

(GILD) Take Advantage of the Fire Sale in Healthcare

InvestmentU — Fri, 19 Aug 2011 00:47:13 +0000

by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now [...]

(GILD) Take Advantage of the Fire Sale in Healthcare

(ONXX) Onyx Analyst Downgrades Shares to Underperform

vitalstocks — Tue, 16 Aug 2011 18:00:35 +0000

We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved sales of the company’s only marketed drug, Nexavar (sorafenib) for cancer, which came in [...]

(ONXX) Onyx Analyst Downgrades Shares to Underperform

(OPTR) Optimer Pharmaceuticals – Bull of the Day

vitalstocks — Mon, 15 Aug 2011 13:56:41 +0000

Optimer Pharmaceuticals’ (OPTR) second quarter 2011 loss per share of $0.52 was wider than the year-ago loss, but we are encouraged by the FDA approval and subsequent launch of Dificid, an antibiotic which treats a condition known as CDAD. Dificid scores better than currently available treatment options on many parameters. Particularly, we believe the inclusion [...]

(OPTR) Optimer Pharmaceuticals – Bull of the Day

(ANX) Company News for August 11, 2011 – Corporate Summary

vitalstocks — Thu, 11 Aug 2011 19:37:31 +0000

• According to a report in The New York Times, Capital One (NYSE:COF) has decided to acquire the U.S. credit card business segment of HSBC holdings (NYSE:HSBC) in a deal estimated to be over $2 billion • MakeMyTrip Limited (NASDAQ:MMYT) posted Q1 EPS of $0.04, surpassing analysts’ consensus estimate of $0.03 per share. Revenues for [...]

(ANX) Company News for August 11, 2011 – Corporate Summary

(MITI) Micromet Loss Less Than Analyst Estimates – Revenues Rise

vitalstocks — Tue, 09 Aug 2011 19:31:29 +0000

Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting for the change in fair value of warrants). The loss was, however, narrower than the Zacks Consensus Estimate of [...]

(MITI) Micromet Loss Less Than Analyst Estimates – Revenues Rise

(ENZN) Enzon Pharmaceuticals’ Weak Top Line Widens Loss

vitalstocks — Tue, 09 Aug 2011 19:23:45 +0000

Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in royalty revenue neutralized the savings from cost-cutting initiatives. The Zacks Consensus Estimate indicated a break-even for the company. Total revenue at Enzon [...]

(ENZN) Enzon Pharmaceuticals’ Weak Top Line Widens Loss

(ACOR) Acorda Therapeutics Gains – Earnings Miss Estimates

vitalstocks — Thu, 04 Aug 2011 15:47:42 +0000

Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during the quarter led to the surge in the company’s [...]

(ACOR) Acorda Therapeutics Gains – Earnings Miss Estimates

(GILD) Gilead Sciences Earnings Grow With HIV Franchise

vitalstocks — Wed, 03 Aug 2011 19:46:42 +0000

Gilead Sciences Inc.’s (GILD) adjusted earnings per share of 95 cents for the second quarter of 2011 were 14 cents above the year-earlier earnings of 81 cents. The earnings growth was driven by a solid top-line performance in the reported quarter. Earnings were however a penny short of the Zacks Consensus Estimate. Second quarter revenues [...]

(GILD) Gilead Sciences Earnings Grow With HIV Franchise

(CTIC) Cell Therapeutics Quarterly Earnings Lag – Company Pares Loss

vitalstocks — Wed, 03 Aug 2011 15:45:32 +0000

Cell Therapeutics (CTIC) suffered a net loss of 14 cents per share in the second quarter of 2011, compared with a net loss of 46 cents (excluding special items) per share in the year-ago quarter. The narrower loss per share in the reported quarter was due to lower operating expenses and lower deemed dividend paid [...]

(CTIC) Cell Therapeutics Quarterly Earnings Lag – Company Pares Loss

(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses

vitalstocks — Wed, 03 Aug 2011 15:34:07 +0000

ViroPharma Inc. (VPHM) posted second quarter fiscal 2011 earnings of 36 cents per share, missing the Zacks Consensus Estimate by 3 cents and the year-ago figure by a penny. Despite higher revenues, earnings bore the brunt of increased operating expenses. Revenues Higher sales from Cinryze boosted the quarterly revenues from $109.0 million in the year-ago [...]

(VPHM) ViroPharma Quarterly Earnings Report Misses Due to Higher Expenses

(ACOR) Company News for August 2, 2011 – Corporate Summary

vitalstocks — Tue, 02 Aug 2011 21:23:12 +0000

• Allstate Corporation (NYSE:ALL) reported Q2 loss of $1.23, lower than the Zacks Consensus Estimate of $1.53 per share. Revenues for the quarter increased by 5% year-over-year to $8.08 billion, exceeding the Zacks Consensus Estimate of $6.91 billion• Auxilium Pharmaceuticals (NASDAQ:AUXL) posted a Q2 loss of $0.11 per share, less than the analysts’ estimate for [...]

(ACOR) Company News for August 2, 2011 – Corporate Summary

(AMGN) Company News for August 1, 2011 – Corporate Summary

vitalstocks — Mon, 01 Aug 2011 16:40:03 +0000

• Chevron Corp. (NYSE:CVX) reported a jump in its second-quarter 2011 profits, benefiting from higher oil prices and stronger refining margins. Earnings per share (excluding adjustments for foreign-currency effects) came in at $3.89, beating the Zacks Consensus Estimate of $3.55 and the year-ago adjusted profit of $2.58 • Amgen Inc. (NASDAQ:AMGN) reported second quarter earnings [...]

(AMGN) Company News for August 1, 2011 – Corporate Summary

(AMGN) Debt Ceiling Debate and Dismal GDP Add To Market Stress

vitalstocks — Sun, 31 Jul 2011 19:36:55 +0000

The debt debate continues to steal the spotlight from earnings and economic reports. The stock market has lost ground in recent days due to this uncertain environment even as corporate earnings reports have broadly come ahead of expectations. With both sides in the debt debate sticking to their positions ahead of the Tuesday deadline, stocks [...]

(AMGN) Debt Ceiling Debate and Dismal GDP Add To Market Stress

(AMGN) Amgen Beats Earnings Expectations – Updates Outlook

vitalstocks — Sat, 30 Jul 2011 19:54:20 +0000

Amgen (AMGN) reported second quarter earnings per share of $1.35, 5 cents above the Zacks Consensus Estimate and 0.7% above the year-ago earnings. Total revenues increased 4% to $3,959 million in the second quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,778 million. US revenues increased 7% during the quarter to $2,975 million. [...]

(AMGN) Amgen Beats Earnings Expectations – Updates Outlook